Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity ...

在近期的美国股市中，礼来公司（Eli Lilly, LLY.US）以超2%的上涨，令市场投资者感到惊喜。周二，该公司股票交易价格达到902.26美元，尽管整体市场情绪受到一定压制，但礼来的这一表现显得尤为亮眼。这一异动的主要原因是礼来宣布将其畅销减肥药Zepbound的小瓶装价格下调，这一举措不仅笼络了消费者，也在市场上引发了广泛关注。

Pharmaceutical giant Eli Lilly is once again expanding the supply of its weight-loss drug Zepbound and cutting the cost for ...

Eli Lilly said it has launched new doses of its obesity treatment drug and reduced its prices.

Eli Lilly released higher doses of its weight loss drug Zepbound in single-dose vials at as much as half its usual monthly ...

Eli Lilly and Company (NYSE: LLY) announced the launch of 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, ...

Lilly expands its Zepbound vial offering, as HIMS pulls back on semaglutide, and other biotech news in today's Readout ...

Eli Lilly said Tuesday that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses ...

Eli Lilly is lowering the cost barrier to its weight loss drug Zepbound.  For many consumers, their insurance denies them ...

Eli Lilly announced a price reduction for its weight-loss drug Zepbound's vials by $50 or more, adapting to stiff competition ...

Eli Lilly ( LLY 2.31%) stock defied today's market downturn, rising 2.6% through 11:15 a.m. ET on the back of two positive ...

Lowering the price of the 2.5 mg dose vial to $349 per month. Lowering the price of the 5 mg dose vial to $499 per month.